-
-
-
-
-
-
-
Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord
-
-
-
-
-
-
-
Ocugen (OCGN) Reports In-Line Q4 EPS
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocugen, Inc. (OCGN)
-
-
-
-
-
-
-
Ocugen (OCGN) Tops Q1 EPS by 1c
-
-
-
-
-
-
-
Ocugen (OCGN) Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for OCU400
-
-
-
-
-
-
-
Ocugen (OCGN) Reports Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
-
-
-
-
-
-
-
Ocugen (OCGN) Prices 30.43M Share Offering at $1.15/sh
-
468,930 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

